Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Merck
Colorcon
Moodys
McKesson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-475

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug TAK-475?

TAK-475 is an investigational drug.

There have been 326 clinical trials for TAK-475. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are one hundred and thirty-one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for TAK-475
TitleSponsorPhase
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1
A Study of TAK-994 in Participants With Narcolepsy Type 1TakedaPhase 1
A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics StudyMillennium Pharmaceuticals, Inc.Phase 1

See all TAK-475 clinical trials

Clinical Trial Summary for TAK-475

Top disease conditions for TAK-475
Top clinical trial sponsors for TAK-475

See all TAK-475 clinical trials

US Patents for TAK-475

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-475   Start Trial Compounds useful for the treatment of metabolic disorders and synthesis of the same North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
TAK-475   Start Trial Fused heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-475   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Tokyo, JP)   Start Trial
TAK-475   Start Trial Peptide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP)   Start Trial
TAK-475   Start Trial Monocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-475   Start Trial Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP)   Start Trial
TAK-475   Start Trial Benzoxazepine compounds, their production and use as lipid lowering agents Takeda Chemical Industries, Ltd. (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-475

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-475 World Intellectual Property Organization (WIPO) 2014165816 2033-04-05   Start Trial
TAK-475 European Patent Office 3275874 2035-03-27   Start Trial
TAK-475 Japan WO2016158788 2035-03-27   Start Trial
TAK-475 World Intellectual Property Organization (WIPO) 2016158788 2035-03-27   Start Trial
TAK-475 Argentina 099399 2034-02-13   Start Trial
TAK-475 Australia 2015216439 2034-02-13   Start Trial
TAK-475 Brazil 112016018548 2034-02-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
AstraZeneca
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.